3 i =x j 1 j 2 i x j 3 i =G(l 1 ,l 2 ,l 3 ,l 4 )u l 1 j 1 u l 2 j 2 u l 3 j 3 u l 4 i x j 1 j 2 i u l 1 j 1 u l 2 j 2 u l 3 j 3 u l 4 i j 1 j 2 j 3 i compounds time points sample gene Gene X target 応用例1: 応用例1: 薬剤投与培養細胞 薬剤投与培養細胞× ×人疾患遺伝子発現 人疾患遺伝子発現 プロファイル統合解析 プロファイル統合解析
with primary biliary cirrhosis”, Drug Des Devel Ther. 2015 ;9:540719. CONCLUSION: Combination therapy improved liver biochemistry and the prognosis of PBC, but did not improve clinical symptoms or incidence of death. Attention should be paid to adverse events when using bezafibrate.
,k 3 ) 1≦k 1 k 2 k 3 5 ≦ k 1 :サンプル k 2 :mRNA k 3 :miRNA 1≦ k 2 5 ≦ G大 G小 1≦ k 3 2 ≦ x jk2 x lk3 ガウス分布仮定 外れ値検出 BenjaminiHochberg 補正P <0.01 χ二乗分布でP値 755miRNA中7miRNA 13393mRNA中427mRNA
CANCER LUMINAL B DN SMID BREAST CANCER BREAST CANCER BASAL DN DOANE BREAST CANCER BREAST CANCER ESR1 UP SMID BREAST CANCER BREAST CANCER RELAPSE IN BONE DN SMID BREAST CANCER BREAST CANCER NORMAL LIKE UP FARMER BREAST CANCER BREAST CANCER BASAL VS LULMINAL BREAST CANCER BREAST CANCER UP SMID BREAST CANCER BREAST CANCER BASAL UP SMID BREAST CANCER BREAST CANCER LUMINAL B UP TURASHVILI BREAST DUCTAL CARCINOMA BREAST DUCTAL CARCINOMA VS DUCTAL NORMAL DN